Increased expression of class III beta-tubulin in castration-resistant human prostate cancer
about
Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Targeting molecular resistance in castration-resistant prostate cancerDrug resistance in castration resistant prostate cancer: resistance mechanisms and emerging treatment strategiesMetastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapyThe many faces of neuroendocrine differentiation in prostate cancer progressionβIII-Tubulin: biomarker of taxane resistance or drug target?Addressing taxane resistance in metastatic castration-resistant prostate cancer: a focus on chaperone proteins.Microtubules and their role in cellular stress in cancerPIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cellsEffect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagyDifferential in vitro sensitivity to patupilone versus paclitaxel in uterine and ovarian carcinosarcoma cell lines is linked to tubulin-beta-III expressionRole of gamma-synuclein in microtubule regulation.Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cellsSlug increases sensitivity to tubulin-binding agents via the downregulation of βIII and βIVa-tubulin in lung cancer cells.Primary versus castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines.Biomarkers for prostate cancer: present challenges and future opportunities.Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.The Prostate Cancer Cells Resistant to Docetaxel as in vitro Model for Discovering MicroRNAs Predictive of the Onset of Docetaxel Resistance.Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.Mechanisms of Therapeutic Resistance in Prostate Cancer.The role of high cell density in the promotion of neuroendocrine transdifferentiation of prostate cancer cells.Cross modulation between the androgen receptor axis and protocadherin-PC in mediating neuroendocrine transdifferentiation and therapeutic resistance of prostate cancer.Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.Novel therapeutic strategies following docetaxel-based chemotherapy in castration-resistant prostate cancer.[Biomarker docetaxel-based chemotherapy].Adaptive pathways and emerging strategies overcoming treatment resistance in castration resistant prostate cancer.Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
P2860
Q26774221-70495723-7239-4F71-9130-7BD9C34C8B5AQ26795445-DB032965-825C-4D9D-B2AE-2614BBD3C231Q26796704-D4B9243E-DB2A-4E01-BE4A-214881211E29Q26825053-10834C4C-D283-423A-9985-8D9D4FC6393CQ26992049-C3D449A0-CD19-4930-A6B6-008A9AEE52FEQ28284878-D07875E7-835C-482F-8E84-9533BDE82C6EQ30244818-74AFA495-36A8-42BA-ACEB-5F2745B95EBDQ33770927-9D240067-7044-492F-BB19-E030CC72BB93Q35068026-DCEAFB60-68EB-4167-9341-FFCAE2DEB8A5Q35678695-E637D966-1B68-4410-930B-78857770D000Q35830854-25742244-A593-481E-9C09-3063566A353CQ35885349-C9AF3E6B-7C5A-40B6-92FF-3D7EEE5D82E2Q36206248-BBD20AE2-A32C-4086-81E7-0EA182FCBE2FQ36804849-20EE78AE-2323-462F-BBDF-503C11E09A50Q37301718-5E18F9BC-0945-405B-8D32-04AC600FCA8EQ37474443-6F10253C-D9A3-4321-84C8-19377AD15B36Q38399930-AA6F2097-8465-4BD8-9A67-E317E47AA19DQ38681199-C0747C59-1607-4BB9-88B0-14478223527EQ38726651-78219B6B-9DE7-485B-A318-98EADCC5C425Q38754316-5CD4EB2C-AEC8-47BE-99F7-B8988C53AC39Q38989505-1C23ECE0-CFC5-459E-866E-CED65B136B6DQ39132563-2C5DA9DB-9717-4F4B-816E-FEEC9B7D32A2Q39138335-FA014100-5A45-4E8B-A052-3352CA0B12FBQ39636515-AA042FC8-B8CC-40E8-806B-0982F497A5B2Q39683668-D7FF0F6E-B17B-47A8-B7D4-832FBC815206Q46262484-F3962C63-B619-4D8B-A4FA-DB8E32BE1487Q53735518-01A5F45B-968E-4014-BFBE-224758379876Q57110000-22E4C473-216B-4F77-8F69-4DFCC061B7DD
P2860
Increased expression of class III beta-tubulin in castration-resistant human prostate cancer
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Increased expression of class ...... esistant human prostate cancer
@en
Increased expression of class ...... sistant human prostate cancer.
@nl
type
label
Increased expression of class ...... esistant human prostate cancer
@en
Increased expression of class ...... sistant human prostate cancer.
@nl
prefLabel
Increased expression of class ...... esistant human prostate cancer
@en
Increased expression of class ...... sistant human prostate cancer.
@nl
P2093
P2860
P356
P1476
Increased expression of class ...... esistant human prostate cancer
@en
P2093
A de la Taille
E Coppolani
F Boissière-Michot
F Vacherot
G Ploussard
N Nicolaiew
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605245
P407
P577
2009-08-18T00:00:00Z